XML 34 R22.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENT (Notes)	9 Months Ended
SUBSEQUENT EVENT (Notes)	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 14—SUBSEQUENT EVENTS TELA Bio In October 2017, the Company made an initial cash investment of $15 million in TELA Bio, Inc., or TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex^TM portfolio of products for ventral hernia repair and abdominal wall reconstruction. The Company may be required to invest up to an additional $10 million in TELA Bio under certain performance scenarios or upon its own election.